Palantir Technologies Inc. PLTR inked a pact with Fondazione Policlinico Universitario A. Gemelli IRCCS, (Policlinico Gemelli), to implement AI-based digital medicine research solutions.
The companies will work towards the development of AI-based digital medicine solutions for healthcare research in Italy.
Policlinico Gemelli's digital research center, Generator RWD, will utilize Palantir Foundry as one of the key enabling platforms to manage the full scale and complexity of healthcare data.
"More and more of the industry is wielding this power to discover novel therapies, improve patient care and increase treatment efficiency and effectiveness," said Andrea Galvagni, Head of Italy at Palantir.
During its Q2 results last month, CEO Alex Karp said PLTR's AI platform has added customers across more than 100 organizations in less than three months.
"The demand for AIP is unlike anything we have seen in the past 20 years. We are currently in discussions with more than 300 additional enterprises to deploy AIP within their organizations," Karp said then.
Also Read: Palantir's AI Euphoria May Fade Due To Lack Of Monetization Strategy: Analyst
Price Action: PLTR shares are trading higher by 1.25% to $15.40 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
